A carregar...
Inhibition of IGF1R Signaling Abrogates Resistance to Afatinib (BIBW2992) in EGFR T790M Mutant Lung Cancer Cells
Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. Acquisition of a secondary mutation in EGFR T790M is the most common mechanism of r...
Na minha lista:
| Publicado no: | Mol Carcinog |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003619/ https://ncbi.nlm.nih.gov/pubmed/26052929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mc.22342 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|